Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study for Continued Durvalumab Treatment in Oncology Patients
2021-003031-29Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Dec 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of durvalumab in transitional cell carcinoma (TCC) and urinary tract cancer, sponsored by AstraZeneca. Primary endpoint: Serious adverse events up to 90 days after last durvalumab dose. Started Dec 2021; status: active.
02
Drugs
durvalumab
03
Conditions
transitional cell carcinoma (TCC)urinary tract cancer
Beyond the preview
Go deeper on 2021-003031-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003031-29.